More than 80% of patients with severe asthma responded to anti-IL-5 biologics in a two-year follow-up study, with 14% of patients being ‘super-responders’ that have no residual manifestations of disease, a registry study shows.

However, predicting who will be a super-responder is difficult and 69% of those treated had residual disease, the Dutch researchers say.

Data for 114 patients with severe eosinophilic asthma treated with mepolizumab, reslizumab or benralizumab in the multicentre Registry of Adult Patients with Severe asthma for 22 Optimal Disease management (RAPSODI) were analysed.

Median age was 66 years at baseline, about 50% were male and follow-up was after two years of anti-IL-5 therapy..